| 000 | 03421nam a22004095c 4500 | ||
|---|---|---|---|
| 999 |
_c5919 _d5919 |
||
| 001 | 5919 | ||
| 003 | ES-MaUEC | ||
| 005 | 20200612111339.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 180731s2019 si a s |||| 0|eng d | ||
| 020 | _a9789811045486 | ||
| 024 | 7 |
_a10.1007/978-981-10-4548-6 _2doi |
|
| 040 |
_bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC849 _b.I34 2019EB |
|
| 245 | 0 | 0 |
_aIgG4-Related Sclerosing Cholangitis _cedited by Terumi Kamisawa, Myung-Hwan Kim. |
| 264 | 1 |
_aSingapore _bSpringer Singapore : _bImprint: Springer _c2019. |
|
| 300 | _aVIII, 142 páginas 54 ilustraciones, 34 ilustraciones a color | ||
| 336 |
_2rdacontent _aTexto (visual) _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 0 | _aMedicine (Springer-11650) | |
| 505 | 0 | _aO verview including classification of sclerosing cholangitis -- Epidemiology -- Pathophysiology -- Pathology -- Clinical features -- Serology -- Diagnostic criteria -- Imaging -- 1) US and CT -- 2) MRI with MRCP -- 3) ERCP -- 4) EUS and IDUS -- Differential diagnosis from primarysclerosing cholangitis -- Differential diagnosis from cholangiocarcinoma -- Tissue acquisition for histologic diagnosis -- Other organ involvements including autoimmune pancreatitis -- Treatment -- 1) Steroids -- 2) Immunomodulatory drugs -- 3) Rituximab -- Prognosis -- IgG4-related sclerosing cholangitis in America -- IgG4-related sclerosing cholangitis in Europe -- IgG4-related disease. | |
| 520 | 3 | _aThis book aims to raise awareness of IgG4-related sclerosing cholangitis among practicing physicians and to equip readers with a sound understanding of the principles of diagnosis and treatment. Clinical, serological, and histopathological features are clearly described and imaging appearances on all relevant modalities are illustrated, covering the bile duct and other involved organs. Differential diagnosis from other diseases, including primary sclerosing cholangitis and cholangiocarcinoma, is precisely explained. Information is then presented on all significant current and emerging therapeutic strategies, including steroids, immunosuppressive drugs, and rituximab. Finally, attention is drawn to significant prognostic features. While IgG4-related sclerosing cholangitis is now a widely acknowledged condition, most practitioners are still liable to misdiagnose it owing to a lack of familiarity with its presenting features. This book should help to rectify the situation and will be an asset for all who may encounter the disease in clinical practice. | |
| 650 | 1 | 4 |
_aInternal Medicine. _0http://scigraph.springernature.com/things/product-market-codes/H33002 |
| 653 | 0 | _aInternal medicine. | |
| 700 | 1 |
_aKamisawa, Terumi. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _995517 |
|
| 700 | 1 |
_aKim, Myung-Hwan. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 |
_aSpringerLink (Online service) _9106937 |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9789811045479 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811045493 |
| 776 | 0 | 8 |
_iPrinted edition: _z9789811338397 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-10-4548-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia) |
| 942 |
_2lcc _cLE |
||
| 998 | _db | ||